Regorafenib in patients with recurrent high-grade astrocytoma

ConclusionsThis retrospective study indicates a very poor performance of regorafenib in recurrent high-grade astrocytoma with a fairly high number of CTC °3 adverse events. In addition, regorafenib does not seem to bear a potential for infiltrative tumor growth promotion.

http://link.springer.com/10.1007/s00432-019-02868-5

Source: Journal of Cancer Research and Clinical Oncology - March 26, 2019 Category: Cancer & Oncology Source Type: research